TVTX Earnings Date: Nov 2, 2026 (Estimated) — Travere Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is TVTX's next earnings date?
Travere Therapeutics, Inc. (TVTX) is expected to report Q3 2026 earnings on Monday, November 2, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.10 on revenue of $195.3M.
How did TVTX do in its last earnings report?
In its most recent report on Aug 4, 2026 (Q2 2026), Travere Therapeutics, Inc. posted EPS of -$0.10 versus the $0.23 estimate, a miss of 143.5%. Revenue was $169.6M against a $159.3M estimate. The stock's 1-day post-earnings move was +12.0%.
How much does TVTX stock move after earnings?
TVTX beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 5.9% (up or down) in the day after earnings.
About Travere Therapeutics, Inc.
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-04 | Q2 2026 | 0.23 | -0.10 | -143.48% | $169.6M | ❌ Miss | +12.03% | +7.48% | +20.01% |
| 2026-05-04 | Q1 2026 | -0.10 | 0.05 | +150.00% | $127.2M | ✅ Beat | -0.24% | -3.12% | +0.65% |
| 2026-02-19 | Q4 2025 | 0.24 | 0.37 | +54.17% | $129.7M | ✅ Beat | +3.72% | +1.43% | -8.40% |
| 2025-10-30 | Q3 2025 | -0.17 | 0.59 | +447.06% | $164.9M | ✅ Beat | +18.58% | +12.31% | +18.68% |
| 2025-08-06 | Q2 2025 | -0.12 | 0.13 | +146.43% | $114.4M | ✅ Beat | -1.91% | +4.70% | +25.52% |
| 2025-02-20 | Q4 2024 | -0.38 | -0.47 | -23.68% | $74.8M | ❌ Miss | -6.79% | -12.47% | -12.93% |
| 2024-10-31 | Q3 2024 | -0.68 | -0.46 | +32.35% | $62.9M | ✅ Beat | -1.44% | -2.56% | +5.94% |
| 2024-08-01 | Q2 2024 | -0.86 | -0.65 | +24.42% | $52.2M | ✅ Beat | -2.60% | -7.68% | +2.49% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $169.6M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Product | 95.1% | $161.4M | — | — | $75.9M | — | $113.2M |
| License | 4.9% | $8.2M | -58.0% | $1.2M | $5.9M | $19.6M | $51.7M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.